ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer

Clin Adv Hematol Oncol. 2006 Aug;4(8):588-90.
No abstract available

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Androgen Antagonists / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / standards*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / blood
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary
  • Disease Progression
  • Disease-Free Survival
  • Docetaxel
  • Humans
  • Male
  • Neoplasm Metastasis
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Quality of Life
  • Survival Rate
  • Taxoids / administration & dosage
  • Treatment Outcome

Substances

  • Androgen Antagonists
  • Antineoplastic Agents
  • Taxoids
  • Docetaxel
  • Prostate-Specific Antigen